Form 8-K - Current report:
SEC Accession No. 0001651308-23-000115
Filing Date
2023-07-24
Accepted
2023-07-24 16:13:34
Documents
14
Period of Report
2023-07-21
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K bgne-20230721.htm   iXBRL 8-K 36368
2 EX-99.1 a20230724formxchmoopinionx.htm EX-99.1 15800
6 image_0.jpg GRAPHIC 85
  Complete submission text file 0001651308-23-000115.txt   186181

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT bgne-20230721.xsd EX-101.SCH 1901
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT bgne-20230721_lab.xml EX-101.LAB 24751
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT bgne-20230721_pre.xml EX-101.PRE 13019
8 EXTRACTED XBRL INSTANCE DOCUMENT bgne-20230721_htm.xml XML 2866
Mailing Address C/O MOURANT GOVERNANCE SERVICES (CAYMAN) 94 SOLARIS AVENUE, CAMANA BAY GRAND CAYMAN E9 KY1-1108
Business Address C/O MOURANT GOVERNANCE SERVICES (CAYMAN) 94 SOLARIS AVENUE, CAMANA BAY GRAND CAYMAN E9 KY1-1108 13459494123
BeiGene, Ltd. (Filer) CIK: 0001651308 (see all company filings)

EIN.: 981209416 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37686 | Film No.: 231105176
SIC: 2834 Pharmaceutical Preparations